News

ABBV

AbbVie Shows Positive Phase 3 Results for Rheumatoid Arthritis Drug

Edward Kim | Equities.com |

Upadacitinib met all primary and ranked secondary trial endpoints including superiority vs AbbVie's own Humira.


AbbVie Could Be a Complete Package for Investors

MoneyShow | Equities.com |

The highest-selling prescription drug in the world is AbbVie's Humira.


AbbVie Announces Positive Results from Second Phase 3 Uterine Fibroids Study

Edward Kim | Equities.com |

Results were consistent with the first Phase 3 study, demonstrating reduction in heavy menstrual bleeding compared to placebo.


Voyager Therapeutics Signs Alzheimer's Gene Therapy Deal with AbbVie Worth up to $1.1 Billion

Edward Kim | Equities.com |

$69 million upfront + up to $155 million in preclinical and Phase 1 options + up to $895 million in developmental milestones.


​Why Myovant is an Emerging Leader in Women’s Health

MoneyShow | Equities.com |

One of the company’s key strengths is its experienced leadership team.


​Biotech AbbVie: Humira and More

MoneyShow | Equities.com |

AbbVie is on track to launch more than 20 new products through 2020.


​AbbVie: Value, Quality & Yield

MoneyShow | Equities.com |

The company's Humira generates tremendous, sustainable cash flow that exceeds cash needed to reinvest in the business.


AbbVie Inc (ABBV) Pops 3.33% for November 21

Equities Staff | Equities.com |

One of the S&P 500’s big winners for Friday November 21 was AbbVie Inc (ABBV) as the company’s stock climbed 3.33% to $67.36 on volume of 9.17 million shares. The stock opened at


IPO Report: Dermira (DERM)

Francis Gaskins | Equities.com |

Dermira ($DERM) is a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients. It is based in Redwood


Biotech Stocks With Considerable Upside Potential

The Life Sciences Report | Equities.com |

Everybody knows that biotech ideas can become huge gainers for investors, but understanding the technology platforms, the unmet needs and the valuations can be daunting, especially in spaces where


Sponsored Financial Content

Market Movers